Weave Bio

Weave Bio is an AI-native, cloud-based software company focused on transforming regulatory workflows in the life sciences industry. The company provides an end-to-end platform that streamlines regulatory content preparation, authoring, review, and lifecycle management for pharmaceutical companies, biotech firms, CROs, and regulatory consultants. By integrating AI into every step of the workflow, Weave aims to accelerate regulatory timelines, improve submission quality, and ensure compliance with global standards like the FDA and EMA. Founded in 2022, the company has gained significant industry attention for its flagship offering, AutoIND, which automates preclinical IND preparation. Weave has expanded its capabilities to cover the entire therapeutic regulatory lifecycle, including clinical and approval-stage submissions. The company is backed by prominent venture capital firms and has established strategic partnerships, such as with the global CRO Parexel, to further enhance its platform and accelerate the delivery of therapies to market.